Research never stops

Publications 2015

Title Source
Evaluation_of_water_displacement_energetics_in_protein_binding_sites_with_grid_cell_theory_Seite_01

Evaluation of water displacement energetics in protein binding sites with grid cell theory

Bodkin M., Law, R., Mazanetz M.P. et al
Phys Chem Chem Phys., 2015, 17, 8416
Modeling_of_ribonucleic_acidligand_interactions_Seite_01

Modeling of ribonucleic acid–ligand interactions

Stefaniak, F., Chudyk, E. I., Bodkin, M. et al.

WIREs Comput Mol Sci 2015
Lal_podocytes_Drug_Disc_Today_2015_Seite_1

Targeting the podocyte to treat glomerular kidney disease

Lal, M. A., Young, K. W., Andag, U.

Drug Discovery Today, 2015, Jun 19 
Jnoff_ChemMedChem_2014_Nrf2-Keap1_inhibitors_UCB_Seite_1

Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex

Jnoff, E., Albrecht, C., Barker, J.J. et al.

ChemMedChem., 2014 April, 9 (4), 699-705

Medchemcomm_2015_IGF1R_Seite_1

Discovery of novel amino-pyrimidine inhibitors of the insulin-like growth factor 1 (IGF1R) and insulin receptor (INSR) kinases; parallel optimization of cell potency and hERG inhibition

Tye, H., Guertler, U., Hofmann, M. H., et al.

Med. Chem. Commun., 2015, 6, 1244-1251
Pareto_Optimization_Identifies_Diverse_Set_of_Phosphorylation_Signatures_Predicting_Response_to_Treatment_with_Dasatinib_Seite_01

Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib

Klammer, M.; Dybowski, J. N.; Schaab, C. et al.

PLoS One 2015, 10 (6), e0128542
Carty_CHDI_EVOTEC_PLOS_ONE_Seite_01

Characterization of HTT Inclusion Size, Location, and Timing in the zQ175 Mouse Model of Huntington´s Disease: An In Vivo High-Content Imaging Study

Carty, N.; Berson, N.; Tillack, K. et al.
PLoS One 2015, 10 (4), e0123527
Targeting_deubiquitinase_activity_with_a_novel_small-molecule_inhibitor_as_therapy_for_B-cell_malignancies_Seite_01

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Peterson, L. F.; Ermann, M.; Courtney, S. M. et al.

Blood 2015, 125, 3588-3597
Systematic_evaluation_of_label-free_and_super-SILAC_quantification_for_proteome_expression_analysis

Systematic evaluation of label-free and super-SILAC quantification for proteome expression analysis

Tebbe, A.; Klammer, M.; Sighart, S. et al.
Rapid Communications in Mass Spectrometry, 2015, 29, 9, 795-801

Evaluation of water displacement energetics in protein binding sites with grid cell theory 

Gerogiokas, G.; Southey, M.W.Y.; Mazanetz, M.P. et al.
Phys. Chem. Chem. Phys., 2015,17, 8416-8426

Synthesis, SAR, and Series Evolution of Novel Oxadiazole-Containing 5-Lipoxygenase Activating Protein Inhibitors: Discovery of 2-[4-(3-{(R)-1-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915)

Takahashi, H.; Crux, R.; Dines, J. A. et al.

J. Med. Chem., 2015, 58 (4), 1669–1690

Identification of 12/15-lipoxygenase as a regulator of axon degeneration through high content screening

Rudhard, Y.; Ghosh,A. S.; Lippert, B.

The Journal of Neuroscience, 2015, 35(7), 2927-2941

Quantitative proteomics of kinase inhibitor targets and mechanisms

Daub., H.

ACS Chemical Biology, 2015, 10, 201-212

Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model

Bartolozzi, A., Albrecht, C., Gemkow, M. et al.

Bioorganic & Medicinal Chemistry Letters, 2015, 25, 587-592

Selective CB2 receptor agonist. Part 2: Structure-acitivity relationship studies and optimization or proline-based compounds

Riether, D., Jenkins, J.E., Albrecht, C. et al.

Bioorganic & Medicinal Chemistry Letters, 2015, 25, 581-586

Selective CB2 receptor agonist. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches

Hickey, E.R., Ermann, M., Albrecht, C. et al.

Bioorganic & Medicinal Chemistry Letters, 2015, 25, 575-580